Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
RUBY Rubius Therapeutics, Inc. daily Stock Chart
RUBY [NASD]
Rubius Therapeutics, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-1.85 Insider Own10.10% Shs Outstand77.78M Perf Week-1.39%
Market Cap661.13M Forward P/E- EPS next Y-2.49 Insider Trans-0.61% Shs Float70.78M Perf Month0.47%
Income-146.20M PEG- EPS next Q-0.60 Inst Own- Short Float14.50% Perf Quarter6.99%
Sales- P/S- EPS this Y-94.90% Inst Trans0.56% Short Ratio26.83 Perf Half Y-16.50%
Book/sh3.88 P/B2.19 EPS next Y-15.30% ROA-32.60% Target Price20.83 Perf Year-41.18%
Cash/sh4.17 P/C2.04 EPS next 5Y- ROE-41.30% 52W Range6.96 - 20.04 Perf YTD-10.53%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-58.23% Beta-
Dividend %- Quick Ratio9.80 Sales past 5Y- Gross Margin- 52W Low20.26% ATR0.51
Employees220 Current Ratio9.80 Sales Q/Q- Oper. Margin- RSI (14)38.82 Volatility5.13% 5.92%
OptionableYes Debt/Eq0.00 EPS Q/Q-78.20% Profit Margin- Rel Volume0.82 Prev Close8.50
ShortableYes LT Debt/Eq0.16 EarningsMar 26 BMO Payout- Avg Volume382.48K Price8.37
Recom2.10 SMA200.87% SMA50-12.91% SMA200-24.39% Volume187,163 Change-1.53%
Jan-31-20Downgrade JP Morgan Overweight → Neutral $9
Sep-10-19Initiated Robert W. Baird Underperform
Jun-26-19Initiated H.C. Wainwright Buy $40
May-31-19Initiated Guggenheim Buy
Aug-13-18Initiated Morgan Stanley Overweight $37
Aug-13-18Initiated JP Morgan Overweight $28
Aug-13-18Initiated Jefferies Buy $40
Jan-30-20 08:00AM  Rubius Therapeutics Announces First Patient Dosed in Phase 1b Trial of RTX-134 for the Treatment of Patients with Phenylketonuria GlobeNewswire
Jan-14-20 08:33AM  BioMarin to Begin Early-Stage Study on Gene Therapy for PKU Zacks
Jan-13-20 02:30PM  'We will deliver in 2020,' Cambridge biotech CEO promises after 2nd trial disappointment American City Business Journals -5.57%
08:00AM  Rubius Therapeutics Announces 2020 Objectives and Provides Operational Update at the 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-08-20 08:00AM  Rubius Therapeutics Appoints Internationally Recognized Autoimmunity and Translational Immunology Leader Laurence Turka, M.D., as Chief Scientific Officer GlobeNewswire +5.22%
Jan-02-20 04:05PM  Rubius Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire -6.53%
Dec-23-19 08:00AM  Rubius Therapeutics Appoints Christina Coughlin, M.D., Ph.D., as Chief Medical Officer GlobeNewswire +10.25%
Dec-21-19 07:18PM  Rubius Therapeutics, Inc. (RUBY): Are Hedge Funds Right About This Stock? Insider Monkey
Dec-19-19 08:00AM  Flagship Unveils Newest Pioneering Platform: Ring Therapeutics PR Newswire -16.57%
Dec-18-19 08:05AM  Rubius Therapeutics Appoints Anne Prener, M.D., Ph.D., to its Board of Directors GlobeNewswire
Nov-14-19 08:00AM  Rubius Therapeutics Reports Third Quarter 2019 Financial Results and Operational Progress GlobeNewswire -19.92%
Nov-12-19 04:05PM  Rubius Therapeutics to Participate in Jefferies London Healthcare Conference GlobeNewswire -8.13%
08:00AM  Rubius Therapeutics Appoints Maiken Keson-Brookes as Chief Legal Officer and Corporate Secretary GlobeNewswire
Nov-08-19 07:00AM  Rubius Therapeutics Highlights Preclinical Oncology Data at Society for Immunotherapy of Cancer Annual Meeting and AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics GlobeNewswire
Nov-05-19 04:05PM  Rubius Therapeutics to Announce Third Quarter 2019 Financial Results GlobeNewswire +12.92%
Nov-04-19 08:00AM  Entrada Therapeutics Appoints Nathan Dowden as Chief Operating Officer PR Newswire -7.40%
Oct-28-19 02:56PM  Should You Buy Rubius Therapeutics, Inc. (RUBY)? Insider Monkey
Oct-17-19 08:00AM  Rubius Therapeutics Announces Oncology Poster Presentations at Upcoming Medical Conferences GlobeNewswire
Sep-03-19 04:05PM  Rubius Therapeutics to Participate in 17th Annual Morgan Stanley Global Healthcare Conference GlobeNewswire -5.28%
Aug-13-19 08:00AM  Rubius Therapeutics Reports Second Quarter 2019 Financial Results and Operational Progress GlobeNewswire
Aug-07-19 04:05PM  Rubius Therapeutics to Announce Second Quarter 2019 Financial Results GlobeNewswire
Jul-25-19 08:00AM  Rubius Therapeutics Appoints Kris Elverum as Senior Vice President of Business Development and Strategy GlobeNewswire
Jul-19-19 03:13PM  Investors Who Bought Rubius Therapeutics (NASDAQ:RUBY) Shares A Year Ago Are Now Down 44% Simply Wall St.
Jun-05-19 08:00AM  Rubius Therapeutics Announces Issuance of Multiple U.S. Patents for its Red Cell Therapeutic Programs GlobeNewswire
May-28-19 04:05PM  Rubius Therapeutics to Present at Jefferies 2019 Healthcare Conference GlobeNewswire
May-23-19 05:27PM  Preclinical biotech Stoke Therapeutics plans $86M IPO American City Business Journals
May-15-19 08:00AM  Rubius Therapeutics Reports First Quarter 2019 Financial Results and Operational Progress GlobeNewswire
May-08-19 02:23PM  In slow year for life science IPOs, this venture firm is making big money American City Business Journals
May-06-19 04:05PM  Rubius Therapeutics to Announce First Quarter 2019 Financial Results GlobeNewswire
Apr-03-19 04:05PM  Rubius Therapeutics to Participate in Jefferies 6th Annual IO Cell Therapy Summit GlobeNewswire
Apr-02-19 08:00AM  Rubius Therapeutics Announces Extensive Preclinical Data for Three Red Cell Therapeutic Oncology Programs at the 2019 American Association for Cancer Research Annual Meeting GlobeNewswire +6.57%
Mar-28-19 08:00AM  Rubius Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results with Business Updates GlobeNewswire
Mar-25-19 12:15PM  How Many Insiders Bought Rubius Therapeutics, Inc. (NASDAQ:RUBY) Shares? Simply Wall St.
08:00AM  Rubius Therapeutics Appoints Natalie Holles to its Board of Directors and Greg Whitehead as Senior Vice President and Chief Quality Officer GlobeNewswire
Mar-19-19 04:05PM  Rubius Therapeutics to Announce Fourth Quarter and Full-Year 2018 Financial Results GlobeNewswire -7.53%
Mar-11-19 08:00AM  Rubius Therapeutics Announces FDA Clearance of Investigational New Drug Application for First-Ever Red Cell Therapeutic, RTX-134, for Treatment of Phenylketonuria GlobeNewswire
Feb-27-19 04:35PM  Rubius Therapeutics Announces Poster Presentations at the 2019 American Association for Cancer Research Annual Meeting GlobeNewswire
Feb-19-19 04:05PM  Rubius Therapeutics to Participate at Upcoming Investor Conferences GlobeNewswire -5.01%
Jan-07-19 08:00AM  Rubius Therapeutics Highlights Upcoming 2019 Milestones at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire -8.05%
Dec-27-18 04:05PM  Rubius Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-21-18 12:15PM  Rubius Therapeutics, Inc. Secures $75 Million Loan Facility GlobeNewswire
Dec-17-18 04:05PM  Rubius Therapeutics Added to Nasdaq Biotechnology Index GlobeNewswire
Dec-16-18 11:16PM  Qatar Fund Building Venture Capital Unit for U.S. Startups Bloomberg
Dec-06-18 08:54PM  Cambridge's Moderna sets record with $604M IPO American City Business Journals -5.18%
Nov-19-18 04:05PM  Rubius Therapeutics to Present at Evercore ISI HealthCONx Conference GlobeNewswire
Nov-13-18 08:00AM  Rubius Therapeutics Reports Third Quarter 2018 Financial Results and Operational Progress GlobeNewswire +19.35%
Nov-06-18 04:05PM  Rubius Therapeutics to Participate in Jefferies London Healthcare Conference GlobeNewswire
Nov-05-18 04:05PM  Rubius Therapeutics to Announce Third Quarter 2018 Financial Results GlobeNewswire
Sep-24-18 10:30AM  Biotech Market is Rolling and These Companies Need to Be on Your Radar ACCESSWIRE
08:41AM  Rubius (RUBY) in Focus: Stock Moves 8.7% Higher Zacks
Sep-20-18 04:05PM  Rubius Therapeutics to Participate in the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology GlobeNewswire
Sep-14-18 04:05PM  Rubius Therapeutics Added to Russell 2000 and 3000 Indexes GlobeNewswire +10.12%
Sep-05-18 03:20PM  How This Biotech IPO Is Facing Off Vs. BioMarin In Metabolic Disease Investor's Business Daily -6.29%
Sep-04-18 04:05PM  Rubius Therapeutics to Participate in the Morgan Stanley 16th Annual Global Healthcare Conference GlobeNewswire
05:36AM  What you missed on your summer vacation in Mass. biotech news American City Business Journals
Aug-31-18 08:00AM  Rubius Therapeutics Reports Second Quarter 2018 Financial Results GlobeNewswire
Aug-21-18 04:05PM  Rubius Therapeutics to Announce Second Quarter 2018 Financial Results GlobeNewswire
Jul-25-18 08:30AM  Rubius Therapeutics to Acquire Manufacturing Facility in Smithfield, Rhode Island to Produce Red Cell Therapeutics GlobeNewswire
Jul-24-18 07:44AM  [$$] Gormley's Take: Public Markets' Embrace of Health Care Extends Beyond Biotech The Wall Street Journal -8.13%
Jul-23-18 08:30AM  Rubius Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Jul-20-18 07:30AM  [$$] Gormley's Take: Biotech Would-Be Acquirers Are Wary Buyers The Wall Street Journal +8.11%
Jul-18-18 11:02AM  Rubius Therapeutics shares surge 35% in trading debut MarketWatch
Jul-17-18 10:44PM  Rubius Therapeutics Announces Pricing of Initial Public Offering GlobeNewswire
Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria. It is also developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. In addition, the company is developing RTX-T1D for treating type 1 diabetes; and RTX-PV for treating pemphigus vulgaris. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CARPENTER CHRISTOPHER L.Chief Medical OfficerDec 16Option Exercise2.8748,000137,76082,843Dec 18 07:50 PM
CARPENTER CHRISTOPHER L.Chief Medical OfficerDec 16Sale13.4848,000646,90134,843Dec 18 07:50 PM
open in yahoo | open in reuters | open in google